Report Overview

UK Lung Cancer therapeutics market size stood at around USD 889 million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of X.X% during the forecast period.

UK is the leading market in lung cancer with a large population base being affected by lung cancer, an increase in the aging population, and augmenting frequent approvals for drug developments. Smoking is thought of as the main cause of lung cancer, though lung cancer also follows in non-smokers. There are around 47,800 new lung cancer cases in the UK every year, that is around 130 every day and Lung cancer incidence rates in England in females are 174% higher in the most deprived quintile compared with the least, and in males are 168% higher in the most deprived quintile compared with the least.



Lung Cancer Stages

There are 4 major stages of lung cancer which is Stage 1, 2, 3 & 4. Stage 1 is part of the number staging system and means your cancer is small. It has not spread to your lymph nodes or other distant organs. Stage 1 can be divided into 1A and 1B. Stage 2 is part of the number staging system. It can be divided into stage 2A and 2B. Part of the affected lung might have collapsed. Stage 2 NSCLC is sometimes called early-stage NSCLC. Stage 3 & $ are very rare and also very less chances of survival at this stage.

Market Driving and Restraining Factors

Driving Factors

The driving factors in the growth of the Lung Cancer therapeutics market includes:

• Rising prevalence


• Increasing patient alertness


• Persistent investment in R&D